Q4 EPS Forecast for Caribou Biosciences Lowered by Analyst

Key Points

• Brookline Capital Markets cut its Q4 2026 EPS estimate for Caribou Biosciences to $0.25 from $0.34, signaling a more cautious outlook for the quarter.
• Caribou’s latest quarterly results beat expectations, with EPS of ($0.26) versus the expected ($0.33) and revenue of $2.40 million, above the $2.21 million estimate.
• Analyst sentiment remains mixed but leans positive overall, with a Moderate Buy consensus and an average target price of $8.00, though shares were trading around $1.94.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Brookline Capital Markets dropped their Q4 2026 earnings per share estimates for Caribou Biosciences in a report issued on Thursday, May 7th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of $0.25 for the quarter, down from their prior estimate of $0.34. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.30) per share.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.07. Caribou Biosciences had a negative return on equity of 84.17% and a negative net margin of 1,189.14%.The company had revenue of $2.40 million during the quarter, compared to analysts' expectations of $2.21 million.

CRBU has been the subject of a number of other research reports. Truist Financial upgraded Caribou Biosciences to a "strong-buy" rating in a report on Wednesday, March 25th. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Caribou Biosciences in a research note on Tuesday, April 7th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Caribou Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $8.00.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $1.94 on Monday. Caribou Biosciences has a 12-month low of $0.75 and a 12-month high of $3.54. The stock has a market cap of $192.41 million, a PE ratio of -1.37 and a beta of 2.27. The business has a 50 day moving average of $1.96 and a 200-day moving average of $1.87.

Institutional Trading of Caribou Biosciences

Several large investors have recently made changes to their positions in the company. Creative Planning acquired a new stake in shares of Caribou Biosciences in the 2nd quarter valued at about $25,000. Bronte Capital Management Pty Ltd. bought a new position in Caribou Biosciences in the 4th quarter valued at about $25,000. R Squared Ltd bought a new position in shares of Caribou Biosciences during the 3rd quarter worth approximately $29,000. Hudson Bay Capital Management LP bought a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $30,000. Finally, Westmount Partners LLC bought a new position in shares of Caribou Biosciences during the 1st quarter worth approximately $37,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company's core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.